← Back to Search
New Roads Open Up For Implementing Immunotherapy In Mesothelioma
R. Cornelissen, M. E. Heuvers, A. Maat, R. Hendriks, H. Hoogsteden, J. Aerts, J. Hegmans
Published 2012 · Medicine
Download PDFAnalyze on Scholarcy
Treatment options for malignant mesothelioma are limited, and the results with conventional therapies have been rather disappointing to this date. Chemotherapy is the only evidence-based treatment for mesothelioma patients in good clinical condition, with an increase in median survival of only 2 months. Therefore, there is urgent need for a different approach to battle this malignancy. As chronic inflammation precedes mesothelioma, the immune system plays a key role in the initiation of this type of tumour. Also, many immunological cell types can be found within the tumour at different stages of the disease. However, mesothelioma cells can evade the surveillance capacity of the immune system. They build a protective tumour microenvironment to harness themselves against the immune system's attacks, in which they even abuse immune cells to act against the antitumour immune response. In our opinion, modulating the immune system simultaneously with the targeting of mesothelioma tumour cells might prove to be a superior treatment. However, this strategy is challenging since the tumour microenvironment possesses numerous forms of defence strategies. In this paper, we will discuss the interplay between immunological cells that can either inhibit or stimulate tumour growth and the challenges associated with immunotherapy. We will provide possible strategies and discuss opportunities to overcome these problems.
This paper references
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
A. Gauvrit (2008)
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
J. Vincent (2010)
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers
R. Hassan (2007)
Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
J. Tol (2010)
Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy.
Henry Ogbomo (2011)
Multifaceted link between cancer and inflammation.
G. Sethi (2012)
Blockade of TGF‐β enhances tumor vaccine efficacy mediated by CD8+ T cells
S. Takaku (2010)
Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
J. D. Veltman (2010)
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
R. Hassan (2010)
The terminology issue for myeloid-derived suppressor cells.
D. Gabrilovich (2007)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10
N. Larmonier (2006)
Regulatory T-cell compartmentalization and trafficking.
S. Wei (2006)
Myeloid-derived suppressor cells as regulators of the immune system
D. Gabrilovich (2009)
Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma.
A. Powell (2006)
The immunobiology of cancer immunosurveillance and immunoediting.
Gavin P Dunn (2004)
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
P. Kantoff (2010)
Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β11
H. Li (2009)
Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo1
D. Powell (2007)
Adoptive T‐cell transfer in cancer immunotherapy
S. Tey (2006)
Immunotherapy for advanced melanoma.
L. Fang (2008)
Interleukin‐2 is essential for CD4+CD25+ regulatory T cell function
Maurus de la Rosa (2004)
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.
A. Mantovani (2002)
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.
B. Huang (2006)
Targeting immune suppressing myeloid-derived suppressor cells in oncology.
J. Kao (2011)
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
R. Kreitman (2009)
Myeloid derived suppressor cells
T. Waldron (2013)
Cyclic adenosine monophosphate is a key component of regulatory T cellmediated suppression
T. Bopp (2007)
Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma
C. Hawrylowicz (2005)
Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.
Smita Nair (2007)
Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.
A. Busse (2011)
Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model
Jedd M. Hillegass (2010)
Modulation of tryptophan catabolism by regulatory T cells
F. Fallarino (2003)
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function
J. D. Veltman (2010)
CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production
A. Thornton (1998)
Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4 + and CD8 + T cells
M Hanson (2009)
A. Mantovani (2008)
Cell Contact–Dependent Immunosuppression by Cd4+Cd25+Regulatory T Cells Is Mediated by Cell Surface–Bound Transforming Growth Factor β
Kazutoshi Nakamura (2001)
Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells.
T. Berger (2005)
Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+CD25+ T cells.
C. Baecher-Allan (2005)
Cytotoxic T lymphocyte antigen‐4‐dependent down‐modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T‐cell‐mediated suppression
C. Oderup (2006)
Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II1
B. Liang (2008)
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma
A. Bograd (2011)
Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma
P. Attia (2005)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
G. Beatty (2011)
M I Garín
Functional coexpression of Interleukin (IL)‐7 and its receptor (IL‐7R) on Hodgkin and Reed‐Sternberg cells: Involvement of IL‐7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma
L. Cattaruzza (2009)
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination
V. V. van Tendeloo (2010)
Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation
Y. Ōnishi (2008)
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
K. Ko (2005)
Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function
P. Fecci (2007)
Heme oxygenase‐1, carbon monoxide, and bilirubin induce tolerance in recipients toward islet allografts by modulating T regulatory cells
Soo Sun Lee (2007)
Inflammation and cancer: back to Virchow?
F. Balkwill (2001)
Regulatory T cells: how do they suppress immune responses?
S. Sakaguchi (2009)
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.
M. Srivastava (2010)
Cell contactdependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor β
K. Nakamura (2001)
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.
F. Colotta (2009)
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
J. Coward (2011)
Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy1
Steve A. Broomfield (2009)
Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo
C. Tadokoro (2006)
History of tuberculosis as an independent prognostic factor for lung cancer survival.
M. E. Heuvers (2012)
CXC chemokines in angiogenesis of cancer.
R. Strieter (2004)
and Developmental Immunology
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy.
A. Sica (2006)
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
P. Sinha (2007)
Dendritic cells as therapeutic vaccines against cancer
J. Banchereau (2005)
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
C. Rooney (1998)
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives
P. Rodriguez (2008)
Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s
R. Bonecchi (1998)
Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.
J. Hegmans (2005)
L-arginine metabolism in myeloid cells controls T-lymphocyte functions.
V. Bronte (2003)
Dendritic cells are the principal stimulators of the primary mixed leukocyte reaction in mice
RM Steinman (1983)
Development of regulatory T cells requires IL-7Ralpha stimulation by IL-7 or TSLP.
R. Mazzucchelli (2008)
TGFβ is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction
S. Byrne (2008)
Points from Letters: Seasonal Charges?
B. Hill (1964)
Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells.
M. Garín (2007)
Cancer—A Biological Approach
M. Burnet (1957)
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
F. Ghiringhelli (2006)
Tolerance, DCs and tryptophan: much ado about IDO.
U. Grohmann (2003)
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
L. Ormandy (2005)
Cancer and the chemokine network
F. Balkwill (2004)
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
J. D. Veltman (2010)
Tumor escape mechanism governed by myeloid-derived suppressor cells.
S. Nagaraj (2008)
EFFECTS OF THE THYMUS LYMPHOCYTOPOIETIC FACTOR *
J. Klein (1966)
Cell contactdependent immunosuppression by CD4 + CD25 + regulatory T cells is mediated by cell surface-bound transforming growth factor β
K Nakamura (2001)
Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer
S. Kusmartsev (2005)
Generation and Accumulation of Immunosuppressive Adenosine by Human CD4+CD25highFOXP3+ Regulatory T Cells*
M. Mandapathil (2009)
Peripherally Induced Treg: Mode, Stability, and Role in Specific Tolerance
I. Apostolou (2008)
CCL2 blockade augments cancer immunotherapy.
Z. Fridlender (2010)
Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma
P. Delong (2005)
Selective Elimination of Human Regulatory T Lymphocytes In Vitro With the Recombinant Immunotoxin LMB-2
Peter Attia (2006)
Immunology of Experimental Tumors
Old Lj (1964)
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.
R. Madan (2010)
Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.
P. Pan (2010)
Cancer immunotherapy comes of age
I. Mellman (2011)
Tumour macrophages as potential targets of bisphosphonates
T. L. Rogers (2011)
Human T cell responses against melanoma.
T. Boon (2006)
Targeting the Effector Site with IFN-αβ-Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors1
A. Currie (2008)
Using Age, Cohort, and Period to Study Elderly Volunteerism
E. Rosenberg (2006)
Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species1
S. Kusmartsev (2004)
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Raffit Hassan (2007)
[Inflammation and cancer].
I. M. Neiman (1974)
Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes.
A. Boissonnas (2010)
Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism1
David C. Gondek (2005)
p300 targeting impairs treg function and promotes host anti-tumor immunity
W. W. Hancock (2012)
Locally administered TLR 7 agonists drive systemic antitumor immune responses that are enhanced by anti - CD 40 immunotherapy
R. G. van der Most
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner
F. Ghiringhelli (2005)
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
Ilona Kryczek (2006)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells
E. M. Hanson (2009)
A. Mantovani (2008)
IL-35-mediated induction of a potent regulatory T cell population
L. Collison (2010)
Macrophages, innate immunity and cancer: balance, tolerance, and diversity.
A. Mantovani (2010)
Induction of Interleukin 10–Producing, Nonproliferating Cd4+ T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells
H. Jonuleit (2000)
Cyclic adenosine monophosphate and IL-10 coordinately contribute to nTreg cell-mediated suppression of dendritic cell activation.
M. Fassbender (2010)
Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin1
Laura Strauss (2007)
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
J. Hegmans (2010)
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
E. Lipson (2011)
Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells.
F. Ebstein (2004)
A denileukin diftitox (Ontak) associated retinopathy?
J. Ruddle (2006)
Mesothelin targeted cancer immunotherapy.
R. Hassan (2008)
Immunology of experimenal tumors
L. J. Old (1964)
Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation
G. Solinas (2009)
Cyclic adenosine monophosphate is a key component of regulatory T cell–mediated suppression
T. Bopp (2007)
Identification and manipulation of tumor associated macrophages in human cancers
M. Heusinkveld (2011)
IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells
S. Rosenberg (2006)
Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cells1
Ilona Kryczek (2006)
Role of tumor-associated macrophages in tumor progression and invasion
A. Mantovani (2006)
This paper is referenced by
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
Novel therapies for malignant pleural mesothelioma.
A. Scherpereel (2018)
Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
E. Marcq (2017)
Macrophages in Mesothelioma : Improving immunotherapy in pulmonary oncology
Sanne Lievense (2017)
Immunotherapy and malignant pleural mesothelioma
Timothy Allen (2018)
Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer.
J. Aerts (2013)
Immunothérapie anti-tumorale dans le mésothéliome pleural malin
A. Scherpereel (2018)
Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
R. Cornelissen (2014)
Alissa Greenbaum (2020)
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
Tumor-associated macrophages in thoracic malignancies.
L. Lievense (2013)
Immunotherapy prospects in the treatment of lung cancer and mesothelioma.
J. Aerts (2014)
Inflammation in malignant mesothelioma - friend or foe?
Anthony Linton (2012)
Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.
R. Cornelissen (2016)
Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
Astero Klampatsa (2017)
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
Nadine L de Boer (2019)
Investigating heterogeneity of growth and drug response in mesotheliomas
Roxanne Otadoy (2013)
Quality evaluation of peach chips and anticancer activity of pectin extracted from chips dehydrated by explosion puffing drying
J. Lyu (2017)
AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral Immunosuppression
Binghao Li (2018)
Improving lung cancer survival; time to move on
M. E. Heuvers (2012)
Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages
Anne-Laure Chéné (2016)
Immune checkpoint blockade in malignant mesothelioma.
Luana Calabrò (2015)
La réponse antitumorale des macrophages dirigée contre les cellules de mésothéliome pleural malin
Clotilde Hoyos (2017)
Current Immunotherapeutic Treatments in Colon Cancer
Z. Dlamini (2016)
Targeting immune checkpoints: New opportunity for mesothelioma treatment?
E. Marcq (2015)